Reducing treatment for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing whether a shorter course of chemo plus an immunotherapy drug called pembrolizumab works as well as the standard longer treatment for early-stage triple-negative breast cancer. The goal is to reduce side effects while keeping the treatment effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with early-stage (stage II) triple-negative breast cancer.
- Your tumor has high levels of immune cells called TILs (at least 30%).
- You are healthy enough for chemo and pembrolizumab, with normal organ function.
- You are able to speak and understand French.
- You are not pregnant or breastfeeding, and you agree to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This trial tests whether using blood tests and imaging during chemotherapy and immunotherapy can help guide treatment for early-stage triple-negative breast cancer. It aims to improve outcomes by adjusting treatment based on how the cancer responds.
This trial is for people with early triple-negative breast cancer who had a strong response to chemotherapy combined with pembrolizumab before surgery. It aims to find the best way to continue using pembrolizumab after surgery to reduce the risk of cancer coming back.
Hear when a new Early Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.